<DOC>
	<DOC>NCT00573430</DOC>
	<brief_summary>To determine the effective dose of candesartan cilexetil for reduction of urinary protein excretion in hypertensive patients with non-diabetic chronic kidney disease with baseline urinary protein/creatinine ratio between 500mg/g and 5000mg/g, by assessing the change in urinary protein/creatinine ratio from baseline to the end of 28-week treatment</brief_summary>
	<brief_title>ARIA (Atacand Renoprotection In NephropAthy Pt.)</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<criteria>hypertension; a)135mmHg &lt; Systolic Blood Pressure &lt;180mmHg and/or 85 mmHg &lt; Diastolic Blood Pressure &lt;100 mmHg. or b) The subject has been treated with antihypertensive medication proteinuria (urinary protein/creatinine ratio between 500 mg/g and 5000 mg/g) Current serumcreatinine &gt; 265 mmol/L (&gt;3 mg/dL). Current serumpotassium &gt; 5.5 mmol/L Known hypersensitivity to angiotensin (AT)1receptor blocker</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Candesartan Cilexetil</keyword>
	<keyword>Non-diabetic Nephropathy</keyword>
	<keyword>hypertension</keyword>
	<keyword>urine protein creatinine ratio</keyword>
</DOC>